Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03307902 | Oct 2016 → Mar 2019 | hepatitis B virus infection | The University of Hong Kong | Completed | No outcome recorded |
| Phase 2/3 | NCT02621112 | Jan 2016 → Dec 2018 | kidney failure | The University of Hong Kong | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT03408730 | Dec 2017 → Oct 2019 | hepatitis B virus infection | VBI Vaccines Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03393754 | Dec 2017 → Apr 2019 | hepatitis B virus infection | VBI Vaccines Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04209400 | Apr 2014 → Apr 2015 | hepatitis B virus infection | VBI Vaccines Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01933412 | Mar 2012 → Aug 2013 | chronic kidney disease, hepatitis B virus infection | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT04531098 | Mar 2006 → Dec 2008 | hepatitis B virus infection | VBI Vaccines Inc. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04179786 | Nov 2015 → Feb 2017 | hepatitis B virus infection | VBI Vaccines Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01133184 | Sep 2010 → Mar 2011 | fibrotic liver disease | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01531075 | Apr 2012 → Aug 2015 | inflammatory bowel disease | Soroka University Medical Center | Completed | No outcome recorded |
| — | NCT01437475 | Nov 2011 → Mar 2013 | HIV infectious disease | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01159457 Comparator | Apr 2011 → Jun 2012 | celiac disease | Shaare Zedek Medical Center | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sci B Vac | “The primary objective of the study is to verify that the manufacturing equivalence of Sci-B-Vac™ is consistent and to compare the immunogenicity and safety of a three-dose...” NCT03408730 ↗14“The study hypothesis is that vaccination with Sci B Vac will achieve a higher seroprotection rate and a higher anti-Hepatitis B surface antibody serum titer level than...” NCT01933412 ↗ “We examined intradermal (ID) HBVv Sci-B-Vac, with topical Toll-like receptor 7 (TLR7) agonist imiquimod pretreatment in dialysis patients.” PMID 32556176 ↗ Jul 2021 “Sci-B-Vac® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 10ug, IM injection at Days 0, 28, and 168.” NCT03393754 ↗ “Each patient will receive a 3 doses Sci-B-Vac™ regime at 0, 1 and 6 months.” NCT03307902 ↗ “Imiquimod ointment + intradermal 10μg Sci-B-Vac vaccine” NCT03307902 ↗ “Sci-B-Vac” NCT04531098 ↗ |
| Known as | 3A-HBV | “Sci-B-Vac®, a 3-antigen hepatitis B vaccine (3A-HBV), contains all three recombinant hepatitis B virus (HBV) envelope proteins (S, pre-S1, and pre-S2).” PMID 34116873 ↗ Jun 2021 |
| Modality | Vaccine | “All newborns received Hepatitis B Immune Globulin within 10 h after birth, as well as active HBV vaccination at 0, 1 and 6 months of age.” PMID 33915943 ↗ Apr 2021 |
| Route | Intramuscular | “will be administered intramuscularly” NCT01159457 ↗ |